Adaptogenics Health sets peptide strategy targeting metabolic health and aging
The Vancouver-listed company is led by CEO J. David Warren, a medicinal chemist who published foundational work on SS-31, now elamipretide.
TR
By Tom Reyes · Markets Editor
Oct 19 13:31 ETSource: Kalkine Media
The wire
- 01Adaptogenics Health Corp (CSE: ADPT) said it will acquire and license peptide and small-molecule assets, design analogues and build delivery technologies across metabolic health, muscle preservation, mitochondrial biology and inflammation resolution.
- 02The company says it will source material from GMP-certified manufacturers and use independent third-party labs to verify identity and purity, and is evaluating GLP-1 companion products for muscle loss and reduced physical function.
- 03Alongside the strategy it named Steven Nguyen CFO, succeeding Ming Jang, and engaged Generation IACP for market making from 19 October 2026 at C$8,500 monthly; no clinical assets or timelines were disclosed.
From the source
Read at kalkinemedia.comAdaptogenics Health Corp (CSE: ADPT) Launches Proprietary Peptide Strategy Focused on Metabolic Wellness and Healthy Aging
Why Is HEALWELL AI (TSX:AIDX) Moving Higher On Watchlists?
